BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 8743334)

  • 1. Clinical pharmacokinetics of therapeutic bile acids.
    Crosignani A; Setchell KD; Invernizzi P; Larghi A; Rodrigues CM; Podda M
    Clin Pharmacokinet; 1996 May; 30(5):333-58. PubMed ID: 8743334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of cholestasis on absorption of ursodeoxycholic acid.
    Sauer P; Benz C; Rudolph G; Klöters-Plachky P; Stremmel W; Stiehl A
    Dig Dis Sci; 1999 Apr; 44(4):817-22. PubMed ID: 10219843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of ursodeoxycholic acid, an enterohepatic drug.
    Hofmann AF
    Scand J Gastroenterol Suppl; 1994; 204():1-15. PubMed ID: 7824870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of metabolism of simultaneously administered chenodeoxycholic acid and ursodeoxycholic acid in hamsters.
    Kihira K; Yamauchi T; Kuramoto T; Une M; Yoshii M; Hoshita T
    Steroids; 1994 Jul; 59(7):431-5. PubMed ID: 7974527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid.
    Piazza F; Montagnani M; Russo C; Azzaroli F; Aldini R; Roda E; Roda A
    Dig Liver Dis; 2000 May; 32(4):318-28. PubMed ID: 11515630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of sulfonate analogs of ursodeoxycholic acid and their effects on biliary bile acid composition in hamsters.
    Mikami T; Kihira K; Ikawa S; Yoshii M; Miki S; Mosbach EH; Hoshita T
    J Lipid Res; 1993 Mar; 34(3):429-35. PubMed ID: 8468526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
    Nakagawa M; Colombo C; Setchell KD
    Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The continuing importance of bile acids in liver and intestinal disease.
    Hofmann AF
    Arch Intern Med; 1999 Dec 13-27; 159(22):2647-58. PubMed ID: 10597755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
    Lanzini A; De Tavonatti MG; Panarotto B; Scalia S; Mora A; Benini F; Baisini O; Lanzarotto F
    Gut; 2003 Sep; 52(9):1371-5. PubMed ID: 12912872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
    Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
    Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment.
    Stiehl A
    Ital J Gastroenterol; 1995 May; 27(4):193-5. PubMed ID: 8520037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol.
    Morton DH; Salen G; Batta AK; Shefer S; Tint GS; Belchis D; Shneider B; Puffenberger E; Bull L; Knisely AS
    Gastroenterology; 2000 Jul; 119(1):188-95. PubMed ID: 10889168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.
    Clayton PT; Mills KA; Johnson AW; Barabino A; Marazzi MG
    Gut; 1996 Apr; 38(4):623-8. PubMed ID: 8707100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosynthesis of N-¹¹C-Methyl-Taurine-Conjugated Bile Acids and Biodistribution Studies in Pigs by PET/CT.
    Schacht AC; Sørensen M; Munk OL; Frisch K
    J Nucl Med; 2016 Apr; 57(4):628-33. PubMed ID: 26697965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.
    Marschall HU; Matern H; Wietholtz H; Egestad B; Matern S; Sjövall J
    J Clin Invest; 1992 Jun; 89(6):1981-7. PubMed ID: 1602004
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.